Skip to main content
SMO ClinPlus CO., LTD. logo

SMO ClinPlus CO., LTD. — Investor Relations & Filings

Ticker · 301257 ISIN · CNE100005CP8 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 483 across all filing types
Latest filing 2025-09-09 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301257

About SMO ClinPlus CO., LTD.

https://www.smo-clinplus.com

SMO ClinPlus CO., LTD. is a professional Site Management Organization (SMO) providing comprehensive clinical trial site management services. The company specializes in supporting pharmaceutical, biotechnology, and medical device developers throughout the clinical development lifecycle. Core services include the provision of Clinical Research Coordinators (CRCs), site feasibility assessments, patient recruitment and retention strategies, and clinical trial data management. ClinPlus facilitates the execution of clinical trials by managing administrative and operational tasks at research sites, ensuring compliance with Good Clinical Practice (GCP) and regulatory requirements. With an extensive network of partner hospitals and research institutions, the company streamlines the clinical research process, enhances data quality, and accelerates project timelines for domestic and international sponsors.

Recent filings

Filing Released Lang Actions
独立董事工作制度（2025年9月）
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and details the rules, responsibilities, qualifications, and procedures related to independent directors of the company 普蕊斯（上海）医药科技开发股份有限公司. It extensively covers governance practices, board structure, director duties, nomination, election, and reporting requirements. There is no financial data, earnings information, or audit results presented. The content is focused on governance and internal rules regarding independent directors, which aligns with the definition of Governance Information (CGR). The document is lengthy and substantive, not a brief announcement or a certification, so it is not RPA or RNS. Therefore, the appropriate classification is Governance Information (CGR).
2025-09-09 Chinese
关联交易决策管理制度（2025年9月）
Governance Information Classification · 95% confidence The document is titled '关联交易决策管理制度' which translates to 'Related Party Transaction Decision Management System'. It outlines the company's policies, definitions, principles, decision procedures, and disclosure requirements regarding related party transactions. The content is a governance and compliance document detailing internal rules and procedures for managing related party transactions, including board and shareholder meeting approvals, disclosure, and conflict of interest avoidance. There are no financial statements, audit opinions, earnings data, or regulatory filings of financial results. The document is a formal internal governance policy rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-09-09 Chinese
关于召开2025年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2025 third extraordinary general meeting of shareholders for 普蕊斯（上海）医药科技开发股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items including amendments to company bylaws and election of a non-independent director, registration details, and attachments such as proxy forms and voting instructions. The content is focused on informing shareholders about the meeting logistics and agenda, not the results of voting or the meeting itself. It is not a report of voting results, nor a management or financial report. It is a formal announcement to shareholders about the upcoming shareholders meeting and how to participate. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-09-09 Chinese
2025年半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the half-year period of 2025. It contains financial data related to related party transactions but does not present a comprehensive financial report or detailed analysis. The document length is short (946 characters) and it is a specific financial summary related to related party transactions rather than a full interim or annual report. It does not fit the definitions of Annual Report, Interim Report, or Earnings Release. It is not a regulatory announcement or certification. The content is focused on related party fund usage and balances, which is typically part of disclosures in financial reports but here presented as a standalone summary. Given the nature and length, the best fitting category is Regulatory Filings (RNS), as it is a specific regulatory disclosure that does not fit other categories.
2025-08-28 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2025 年半年度报告摘要" which translates to "2025 Half-Year Report Summary." It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also includes management discussion on business operations, market conditions, and strategic outlook. The length of the document (5867 characters) and the presence of substantive financial data and analysis confirm it is a financial report rather than a brief announcement or certification. The document corresponds to an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year (half-year).
2025-08-28 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 普蕊斯（上海）医药科技开发股份有限公司 regarding the approval of the 2025 semi-annual report and a special report on the use of raised funds. It states that the Supervisory Board has reviewed and approved the 2025 half-year report and the fundraising usage report, confirming compliance with relevant laws and regulations. The document does not contain the actual financial statements or detailed financial data but refers to the full reports published elsewhere (on 巨潮资讯网 and newspapers). The document length is short (1159 characters) and serves as an official announcement of the Supervisory Board's meeting resolutions rather than the report itself. According to the classification rules, such announcements that confirm or summarize approval of reports without containing the full report content should be classified as Regulatory Filings (RNS).
2025-08-28 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.